Abstract
FerGene has launched with more than $570 million in funding from Ferring Pharmaceuticals and Blackstone Life Sciences to bring to market nadofaragene firadenovec, a bladder cancer gene therapy. Most of the money—$400 million—comes from Blackstone, an investment firm. Ferring licensed the adenovirally mediated interferon alfa-2b gene therapy last year from FKD Therapies, which had bought it from Merck & Co. in 2011. Ferring later filed for US approval of the treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
